Rapid Micro Biosystems (RPID) 44th Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
44th Annual J.P. Morgan Healthcare Conference summary
15 Jan, 2026Business overview and market context
Automates microbial quality control in pharmaceutical manufacturing, replacing manual Petri dish methods with the Growth Direct Platform.
Operates in about 20 countries, serving 75% of the global top 20 pharma companies and 86% of approved CAR-T manufacturers, excelling in biologics and cell/gene therapy.
190 systems placed globally, with 155 validated for routine use and presence at over 100 customer manufacturing sites.
Recurring revenue forms a strong base, with over half of annual revenue from consumables and service contracts, and over 9 million consumables sold.
The platform is modality-agnostic, integrates with customer data systems, and supports applications like environmental monitoring, water testing, bioburden, and rapid sterility testing.
Financial performance and growth
Achieved $34 million in 2025 revenue, up 20% year-over-year, with $18 million in recurring revenue and 53% of total revenue.
Q4 revenue reached $11.3 million, a 37% increase year-over-year, with 16 systems placed and 3 validated.
13 consecutive quarters of meeting or exceeding revenue guidance, with strong gross margin growth.
Reinforced balance sheet with a $45 million facility, ending 2025 with $38 million in cash.
Record multi-system order from an existing customer, expanding globally and adopting all core applications.
Strategic initiatives and partnerships
Land and expand strategy: initial system placements followed by network-wide expansion and application onboarding.
Innovation focus includes expanding platform capabilities and targeting adjacent markets like food, beverage, and medical devices.
Partnership with MilliporeSigma aims to drive growth, margin expansion, and access to new markets, with significant impact expected in 2026.
Commercial momentum supported by multi-system orders and expanding recurring revenue from consumables and services.
Annual Growth Direct Day event fosters customer engagement, with the 7th edition hosting over 25 companies and 100 attendees from the U.S., Europe, and Asia.
Latest events from Rapid Micro Biosystems
- 2026 targets strong revenue growth, margin gains, and broad market expansion through automation.RPID
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Record revenue growth and major system orders drive strong 2026 outlook and margin expansion.RPID
Q4 202512 Mar 2026 - Record revenue and automation drive global growth and innovation in microbial quality control.RPID
TD Cowen 46th Annual Health Care Conference6 Mar 2026 - Record Q2 revenue, margin gains, and cost actions set path to positive cash flow by 2027.RPID
Q2 20242 Feb 2026 - Growth Direct platform drives record growth, operational efficiency, and expanding pharma adoption.RPID
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Record Q3 revenue, positive margin, and strong system placements support 2027 cash flow goal.RPID
Q3 202417 Jan 2026 - Automated QC adoption rises, multi-system orders grow, and new products drive 2025 optimism.RPID
Stifel 2024 Healthcare Conference13 Jan 2026 - Record 2024 revenue and automation innovation set the standard in automated pharma QC.RPID
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Automated platform accelerates microbial quality control, fueling rapid global growth and innovation.RPID
H.C. Wainwright 27th Annual Global Investment Conference31 Dec 2025